This study indicated that PVT1 promoted the progression of ccRCC partly through activation of the epidermal growth factor receptor pathway.[44] These findings suggest that PVT1 may be an oncogenic biomarker for ccRCC, and the PVT1 associated pathway may serve as a novel therapeutic target for treating ccRCC. This evidence concerns the gene EGFR and nonpapillary renal cell carcinoma.